Novel Regulation of Cortical Acetylcholine Release and Cognitive Behavior by Gardner, Kristen
Page 1
1
Novel Regulation of Cortical Acetylcholine Release and Cognitive Behavior
A Senior Honors Thesis
Presented in Partial Fulfillment of the Requirements for graduation with research distinction
in the undergraduate colleges of The Ohio State University
Kristen Gardner
The Ohio State University
June 2008
Project Advisor
 Dr. John P. Bruno
Professor of Psychology, Psychiatry, and Neuroscience
Page 2
2
DEDICATION
I wholeheartedly dedicate this work to my husband, David, my parents, and the rest
of my family for their continued care, love, and encouragement throughout my life.
Page 3
3
ACKNOWLEDGEMENTS
First and foremost, I would like to express my gratitude towards Dr. Bruno for his
guidance, mentorship, and inspiration. For the past year, I have had the privilege of working
in his laboratory and learning about the neuropsychopharmacology of schizophrenia. He
has served as an excellent role model of perseverance and dedication, and the
opportunities that I have experienced will last throughout my lifetime. The knowledge and
lessons that I have gained through his mentorship will be invaluable as I further my
education.
I would like to thank the College of Biological Sciences, Department of Microbiology
for its financial contribution to my undergraduate education through the Anne H. Baumhofer
Scholarship. In addition, I would also like to thank the college for specifically funding my
undergraduate research through the Dean’s Undergraduate Research Fund. My gratitude
to The College of Social and Behavioral Sciences for contributing to this research project
through a grant awarded in the 2007 scholarship competition. Additionally, I would like to
thank the College of the Arts and Sciences for contributing to my undergraduate education
through the ASC Undergraduate Research Scholarship Competition in the fall of 2007.
I would also like to express my gratitude to all the members of the lab for their help
and collaboration with so many different aspects of my project: Amy Zmarowski, Katie
Alexander, Julie Brooks, CR Gash, Åsa Konradsson, and all the undergraduate researchers
as well.
I would like to especially thank my major advisor, Dr. Juan Alfonzo, through the
Department of Microbiology, and my honors advisor, Joanna Spanos, through the College
of Arts and Sciences Honors Department, for their guidance throughout my undergraduate
education. Finally, I would like to thank Dr. Randy Nelson of the Psychology Department
and Dr. T.V. Rajanbabu of the Chemistry Department for donating their time and serving as
committee members for my thesis defense.
Page 4
4
TABLE OF CONTENTS
Abstract………………………………………………………………………….. Page 5
Introduction…………………………………………………………………….. Page 7
Materials and Methods………………………………………………………... Page 14
Results...…………………………………………………………………………. Page 21
Discussion……….……………………………………………………………… Page 25
Future Directives……………………………………………………………….. Page 30
Conclusion………………………………………………………………………. Page 30
Figures and Figure Legends…………………………………………………. Page 31
References………………………………………………………………………. Page 37
Page 5
5
ABSTRACT
There is an evolving literature demonstrating the ability of non-neuronal cells to
regulate the release of traditional neurotransmitters within various brain regions.
Specifically, astrocytes may play a more substantial role in regulating chemotransmission
than previously thought. Anatomically, astrocytes lie in close apposition to neurons and can
functionally impact neuronal signaling through generation of neuroactive compounds like
kynurenic acid (KYNA), a byproduct of the kynurenine pathway (KP) of the metabolism of
tryptophan. Endogenous levels of KYNA antagonize _7 nicotinic ACh receptors (nAChR).
As such, KYNA can regulate the release of traditional neurotransmitters like glutamate and
dopamine which have the ability to positively modulate acetylcholine (ACh) levels in the
medial prefrontal cortex (mPFC). Given the essential activity of nAChR in cognitive
behaviors such as attentional processing, dysregulations in the KP may be functionally
significant as elevated levels of cortical KYNA have been associated with schizophrenia.
Furthermore, schizophrenic patients also display severe cognitive deficits in executive
functioning characterized by impaired cognitive flexibility. Performance in tasks that
measure cognitive flexibility, such as perceptual set shifting, is dependent upon the integrity
of prefrontal activity. As such, this project has two specific aims. The first determines the
ability of local KYNA to modulate basal cortical ACh release in the mPFC. Male Wistar rats
were implanted with microdialysis guide cannulae into the mPFC, and the rats were
perfused, in randomized order, with the following drug treatments; artificial cerebral spinal
fluid (aCSF) as a vehicle control, KYNA (100 nM), a kynurenine aminotransferase II (KAT II)
inhibitor, UPF-874 (5 mM), and KYNA (100 nM) + UPF-874 (5 mM). We discovered that
KYNA bi-directionally modulates basal ACh release in the mPFC as KYNA attenuated ACh
release and inhibition of its synthesis by UPF-874 potentiated ACh release locally within the
mPFC. The second aim determined whether varying KYNA levels was associated with a
type of cognitive deficit observed in schizophrenia. Male Wistar rats were tested in a
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prefrontally-mediated set-shifting task which required two session of testing on consecutive
days. On day 1 (Set 1), animals are trained to discriminate between brightness (black
versus white) or texture (smooth versus rough) dimensions, until reaching a criterion
performance level (8 consecutive correct trials). On day 2 (Set 2), animals are trained on
the alternative (extra-dimensional) discrimination strategy for 80 trials, regardless of
performance. Animals received either a systemic injection of saline or kynurenine (50
mg/kg) prior to testing on Set 1 or Set 2. We discovered that elevated KYNA levels
specifically impaired the ability of animals to perform an EDS that was not due to a general
cognitive impairment as increasing levels of this metabolite did not impair rule acquisition.
Collectively, these studies indicate a role for KYNA dysfunction in schizophrenia. Therefore,
drugs which inhibit or decrease the production of KYNA (ie. KAT II inhibitors) may be
effective pharmacotherapies for the treatment of cognitive deficits observed in
schizophrenia.
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INTRODUCTION
1.1 Schizophrenia
Schizophrenia is one of the most severe and debilitating neuropsychiatric disorders
and may affect up to 1% of the general population (Carpenter and Buchanan, 1994).
Although significant advances have been made both in terms of understanding its
pathophysiology and treatment strategies, the prognosis for schizophrenia is poor and
treatment remains a major challenge in mental health care. This may be partially explained
by the fact that schizophrenia is associated with a multiplicity of symptoms including
positive symptoms, negative symptoms, and cognitive dysfunction (Andreasen, 1995).
Positive, or psychotic, symptoms include hallucinations, delusions, and thought disorders
whereas negative symptoms include a flattened affect or social withdrawal.  In addition,
patients present with severe cognitive impairments as many domains of cognition are
differentially disrupted, one of which includes executive functions like attention and
cognitive flexibility (Andreasen, 1995). This aspect of the schizophrenia is critical because
these impairments often accompany (Saykin et al., 1994) or precede (Fuller et al., 2002)
the onset of psychosis, and remain throughout the course of the illness (Green & Braff,
2001). More importantly, the severity of cognitive dysfunction is positively correlated with
the decline in quality of life of patients with schizophrenia (Green et al., 1996). Antipsychotic
medication is a standard treatment strategy for individuals diagnosed with the disease. The
use of newer atypical antipsychotics is commonplace, and while they demonstrate
increased efficacy treating positive and negative symptoms with fewer extrapyramidal side
effects, they do not completely alleviate the neurocognitive deficits (Peuskens et al., 2005).
Therefore, understanding the regulation of neural systems that are involved in cognitive
functioning is critical for the development of more efficacious pharmaceutics to normalize
the cognitive impairments observed in schizophrenia.
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1.2 Basal Forebrain Cholinergic System and Regulation of Acetylcholine
One neural system whose activity has been demonstrated to be essential in normal
attentional processing, which is a necessary early mediator of cognitive function (Sarter &
Bruno, 1997), is the basal forebrain cholinergic
system (BFCS). The integrity of attentional
processing is mediated by acetylcholine (ACh)
innervation of the prefrontal cortex (PFC) that is
supplied from the cholinergic neurons originating
from the nucleus basalis of Meynert / substantia
innominata (SIO) region of the BF (Figure 1;
Sarter et al., 2005). In fact, impairments in task
performance are evident following selective lesions of basal forebrain cholinergic neurons
projecting to the cortex (Dalley et al., 2004). Furthermore, these projections terminating in
the PFC are necessary for the expression of executive functions like attention and cognitive
flexibility (Birrell & Brown, 2000). It has been proposed that aberrations within this system
may contribute to the cognitive deficits observed in various neuropsychiatric disorders
(Sarter & Bruno, 1999). As such, the identification of regulatory mechanisms mediating ACh
transmission is increasingly relevant to understand and effectively treat the cognitive
deficits associated with schizophrenia.
1.3 Non-Neuronal Modulation of Chemotransmission
Previously, the regulation of chemotransmission exclusively focused on the
modulation by other traditional neurotransmitter systems. For instance, it has been
demonstrated that two neurotransmitters, dopamine (DA) and glutamate (Glu) are capable
of positively modulating ACh release in the PFC (LaPlante et al., 2004; Del Arco et al.,
2007). Additionally, this regulatory capacity also extends to the distal, yet functionally
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related nucleus accumbens (NAC) (Figure 1). This brain region is relevant because
afferents that synapse in the BF release the inhibitory neurotransmitter γ-aminobutyric acid
(GABA). Therefore, these projections from the shell region of the NAC act as a critical
modulator of BFCS excitability. Dopamine (DA) and glutamate (Glu) interactions regulate
the excitability of these NAC projections (Ariano et al., 1997) and, as a result, the activity of
the BFCS and ACh levels in the PFC. Therefore, it has been shown that local
pharmacological manipulations in the NAC are capable of trans-synaptically regulating
cholinergic transmission in the distal, yet functionally related, PFC as well as locally
regulating cortical ACh transmission.
1.4 Kynurenine Pathway
In contrast to the regulation of chemotransmission by other neurotransmitter
systems and other brain regions, it is becoming increasingly evident that astrocytes and
other non-neuronal support cells may play a more substantial role in neuronal
communication than indicated by their typical biochemical supportive functions.
Anatomically, astrocytes lie
in close apposition to
neurons (Haydon, 2001) and
can functionally impact
neuronal signaling through
the generation of neuroactive
compounds like kynurenic
acid (KYNA), a metabolite of
the kynurenine pathway (KP)
of tryptophan degradation
(Figure 2; Schwarcz et al., 2001). Initially, KYNA was reported to be a broad-spectrum
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antagonist of excitatory amino acid (EAA) receptors, it was later discovered that the
metabolite possessed neuroprotective properties mediated through inhibition of the glycine
co-agonist (glycineB-receptor) of the NMDA receptor (Foster et al., 1984). However, KYNA
must compete with glycine, which has an approximately 20x higher affinity for the receptor
than KYNA (Parsons e al., 1997), and D-serine, a potent agonist of the site (Schell, 2004),
for access to the glycineB-receptor. At nanomolar concentrations, this metabolite is also a
potent, non-competitive antagonist of _7 nicotinic acetylcholine receptor (_7nAChR; Hilmas
et al., 2001). The previous data, in conjunction with other studies, provides much evidence
for the proposition that _7nAChR rather than the glycineB-receptors are the primary in vivo
target of nanomolar concentrations of KYNA in the striatum (Alkondon et al., 2004; Hilmas
et al., 2001; Wu et al., 2007).
1.5 Kynurenic Acid and Regulation of Neurotransmitter Release
As KYNA is a natural constituent in the mammalian brain it may play a role in brain
physiology, and especially pathology, as KYNA is an antagonist of both the NMDA receptor
(Schwarz & Pellicciari, 2002) and the _7nAChR (Hilmas et al., 2001). The fact that KYNA is
capable of interacting with both of these Ca2+ permeable receptors suggests a physiological
function in glutamatergic and cholinergic neurotransmission. Interestingly, dysregulations in
the KP have been implicated in various disease states that are also characterized by
glutamatergic and cholinergic abnormalities (Nemeth et al., 2005). In fact, direct support for
such a regulatory role has been provided by in vivo studies in the rat striatum where a
reduction in KYNA levels enhances vulnerability to an excitotoxic insult (Poeggeler et al.,
1998), and conversely, modest elevations of KYNA inhibit glutamate release (Carpendo et
al., 2001). Furthermore, changes in KYNA levels also influences another neurotransmitter,
DA, as comparatively modest increases in KYNA reduces extracellular DA levels
(Rassoulpour et al., 2005) while reductions elevate extracellular levels (Wu et al., 2007).
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Since both DA and Glu positively modulate ACh levels, KYNA may influence BFCS activity
by negatively modulating ACh release (Del Arco et al., 2007; LaPlante et al., 2004).
1.6 Biochemistry of Kynurenine Pathway
Therefore, given the ability of KYNA to regulate both DA and Glu release, and its
potential to influence ACh transmission, understanding the fundamental principles
underlying its synthesis is essential. While endogenous levels of KYNA are influenced by
metabolic processes (Hogkins et al., 1998), they are primarily controlled by the
bioavailability of its precursor L-kynurenine (L-KYN), which readily crosses the blood brain
barrier from the peripheral circulation. Although the majority of L-KYN is peripherally
derived, enzymes responsible for its formation are also located in the brain (Guidetti et al.,
1995). The precursor is then actively transported into astrocytes by a sodium-independent
transporter for large neutral amino acids (Speciale, 1989); however, a less efficient,
sodium-dependent mechanism also transports KYN into neurons (Speciale & Schwarcz,
1990). Subsequently, KYNA is formed through the irreversible transamination of KYN by
kynurenine aminotransferases (KATs) I and II (Okuno et al., 1991). KAT II, which is
preferentially responsible for the de novo synthesis of KYNA as this enzyme operates best
at physiological pH and preferentially recognizes L-KYN as a substrate (Guidetti et al.,
1997, 2007a), is primarily localized in astrocytes as demonstrated by immunocytochemical
studies (Guidetti et al, 2007b). After synthesis, KYNA is rapidly liberated into the
extracellular space through a calcium-independent process (Turski et al., 1989), but the
precise mechanism has not been elucidated. Interestingly, KYNA cannot be removed from
the extracellular space by re-uptake or enzymatic degradation (Turski & Schwarcz, 1988)
so transport by a non-specific probenecid-sensitive process appears to be the only mode by
which KYNA is eliminated from the brain (Moroni et al., 1988). In accordance, probenecid
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adminisration to rats is associated with elevated concentrations of endogenous kynurenic
acid in the brain (Erhardt et al., 2002).
Obviously, this pathway can be manipulated to vary endogenous levels of KYNA in
order to test hypotheses. For instance, direct perfusion of KYNA or increasing precursor
levels of L-KYN would elevate KYNA levels. In contrast, interfering with the biosynthetic
machinery of its synthesis through inhibiting KAT II would decrease levels of KYNA.
1.7 Kynurenic Acid and Schizophrenia
Considering the previous evidence that demonstrates a physiological role for KYNA,
such as the modulation of other neurotransmitter systems and its preferential inhibition of
_7nAChR, manipulations of the KP would be a useful method to elucidate the mechanisms
mediating its biological function(s). Given the essential activity of _7nAChR in cognitive
behaviors such as attentional processing (Dani & Bertrand, 2007), dysregulations in the KP
may be functionally significant. Interestingly, elevated levels of cortical KYNA have been
associated with schizophrenia and the increases were seen only in the prefrontal cortex, a
cortical area traditionally thought to be involved in the pathophysiology of the disorder
(Schwarcz, 2001). Furthermore, schizophrenic patients also display severe cognitive
deficits in executive functioning characterized by impaired cognitive flexibility (Ragozzino,
1999). This refers to a humans’ or animals’ ability to shift behavioral response strategies
when there is a change in environmental contingencies. Performance in tasks that measure
cognitive flexibility, such as perceptual set-shifting, therefore requires the organism to shift
attention to different dimensions of the stimulus array based on changes in rules or rewards
encountered during the course of a problem-solving task (Owen et al., 1991). Perceptual
set-shifting in humans is typically assessed using variants of the Wisconsin Card Sorting
Task (WCST; Robbins, 2007). Extensive evidence indicates that individuals with
schizophrenia and other patients with PFC damage perform poorly on the WCST (Pantelis
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et al., 1999). The maze-based set-shifting task was developed to reveal many of the same
cognitive operations highlighted by the WCST (Birrell & Brown, 2000). There is
considerable evidence in both primates (Dalley et al., 2004) and rats (Birrell & Brown, 2000)
indicating that the integrity of prefrontal function strongly influences the quality of
performance in set-shifting tasks. Additionally, discrimination amongst novel, complex
stimuli is more rapid when the discrimination rule is based on the same perceptual
dimension (i.e. intradimensional shift, ID) rather than to a different perceptual dimension
that was previously irrelevant to solving the task (i.e. extradimensional shift, EDS; Birrell &
Brown, 2000). As such, performance deficits in the WCST by schizophrenic patients
typically reflect reduced performance on the EDS component of the task (Jazbec et al.,
2007).
1.8 Hypotheses
Overall, given the ability of KYNA to negatively modulate neurotransmitter systems
that positively modulate ACh transmission, and based on data implicating elevations in
KYNA in the pathophysiology of schizophrenia, we propose KYNA may have a regulatory
capacity over the BFCS as well. We therefore, conducted two experiments to test the role
of KYNA in the regulation of cortical ACh release and cognitive behavior. The first
experiment tested the capacity of KYNA to modulate basal ACh transmission in the medial
prefrontal cortex (mPFC) and then extended this modulation to the role of endogenous tonic
concentrations of KYNA. The second experiment used a set-shifting task as a measure of
cognitive flexibility to reveal a role for KYNA in the regulation of prefrontally-mediated
cognitive behavior. We propose that if the astrocyte-derived metabolite KYNA has a critical
role in the regulation of basal ACh transmission, then changes in extracellular levels of
KYNA will modulate ACh release locally in the PFC. Furthermore, as schizophrenics
present with impairments in cognitive flexibility, an executive function mediated by
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prefrontal activity, and elevated KYNA levels, increases in this metabolite may result in
impaired flexible responding.
MATERIALS AND METHODS
1. SUBJECTS
Male Wistar rats (Charles River Labs, Wilmington, MA, USA) weighing between
300-400 grams were utilized for all studies.  Animals were maintained on a 12:12 hour
light:dark cycle (lights on: 0600) in a temperature- and humidity-controlled room.  Animals
were individually housed in plastic cages lined with corn cob bedding (Harlan Teklad,
Madison, WI, USA) and had access to food and water ad libitum.  All procedures involving
animals were approved by The Ohio State University Institutional Animal Care and Use
Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Three days prior to surgery, animals were acclimated to the microdialysis testing
environment in clear plastic bowls (35 cm height x 38 cm diameter; CMA, Stockholm,
Sweden) lined with corn cob bedding.  Animals remained in the bowls for a minimum of four
hours/day, and returned to their home cages at the end of each acclimation period.
2. SURGERY
Following their three days of acclimation, animals were anesthetized using
isoflurane gas (2%, 0.6 L/min, O2 delivery) and unilaterally implanted with microdialysis
guide cannula (0.38 mm o.d.; Sci Pro Inc., Sanborn, NY, USA) into the mPFC (A = 4.2, L =
±0.6, V = 0.6 mm, 20º rostral angle relative to Bregma and dura). All guide cannula are
fixed to the skull using stainless steel screws and dental acrylic.  Stylets, ending flush with
the guide cannula, were inserted to prevent cannula occlusion.  The surgical site was
swabbed with a topical antibiotic ointment (lidocane, 5%), and animals also received a
Page 15
15
prophylactic dose of the antibiotic chloroamphenicol (100 mg/ml; 0.125 ml) administered
subcutaneously.   Following surgery, animals were returned to their home cages and
allowed to recover for 4 days prior to microdialysis testing or resuming behavioral training.
3. GENERAL MICRODIALYSIS PROCEDURES
Microdialysis sessions were conducted using repeated perfusions, with each animal
receiving four different pharmacological manipulations, one every other day.  This repeated
testing paradigm has the advantage of decreasing variability among treatment conditions
because each subject serves as its own control.  Furthermore, it allows for paradigms such
as dose-response analyses, as well as agonist-antagonist interactions to be studied in the
same animal.  The procedure has been repeatedly validated by demonstrating that basal
cortical ACh efflux does not significantly change over repeated dialysis sessions, and that
the effects of behavioral, pharmacological, or sensory manipulations on ACh levels do not
interact with dialysis sessions (Bruno et al., 1999; Nelson et al., 2002).
On the fourth day following surgery, animals were brought to the testing
environment and allowed to acclimate for 30 minutes prior to the insertion of microdialysis
probes.  Following the 30-minute acclimation period, stylets were removed and probes (Sci
Pro, Inc., 0.2 mm o.d., 3 mm membrane tip for PFC) were inserted into each guide.  Inlet
and outlet lines for the dialysis probes were attached to a two-channel liquid swivel
(Instech, Plymouth Metting, PA).
Probes were continuously perfused with artificial cerebral spinal fluid (aCSF)
(containing in mM: NaCl 166.5, NaHCO3 27.5, KCL 2.4 CaCl2 1.2, Na2SO4 0.5, KH2PO4 0.5,
glucose 1.0, pH 7.1) at a flow rate of 1.25 µl/min.  No acetylcholinesterase inhibitor was
utilized in any experiment.  A three-hour wash out period was observed after probe
insertion to allow ACh efflux to reach a stable baseline that was maximally sensitive to TTX
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before beginning collections (Moore et al., 1992).  All microdialysis experiments conducted
followed this general paradigm.
Microdialysis for animals participating the set shifting tests will be conducted in a
similar manner except all post-surgical acclimation will be done in the maze itself and on
each day of testing, animals will be placed into the start arm and barricaded there for a 2-
hour wash-out period prior to task onset.  Artificial CSF will be perfused throughout the
sessions and ACh will be collected every 8 minutes (flow rate: 2.0 µl/min) once the task
begins.
4. HPLC ANALYSIS
ACETYLCHOLINE
Dialysis samples were stored at -80º C until analyzed using high performance liquid
chromatography (HPLC) with electrochemical techniques.  A volume of 15 µl of each
sample was injected by an autosampler (ESA Inc., Chelmsford, MA).  ACh and choline
were separated by a UniJet microbore analytical column (BAS Inc.; 1 x 50 mm) using a
sodium phosphate mobile phase (35 mM Na2HPO4, 0.36g EDTA, 1.0% of the microbicide
Proclin, pH = 8.5), flowing at 0.15 ml/min.  A post-column IMER containing
acetylcholinesterase and choline oxidase was used to break down ACh into H2O2 (Potter et
al., 1983), and quantified using a peroxidase-wired glassy carbon electrode.
KYNURENIC ACID
KYNA levels were analyzed using HPLC with florescence detection (excitation
wavelength: 344nm; emission wavelength: 398nm) by our collaborators at the University of
Maryland (Wu et al., 2007).
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5. HISTOLOGY
Following the final microdialysis session, animals were given an overdose of sodium
pentobarbital and trans-cardially perfused with 0.9% heparinized saline followed by 10%
formalin.  Brains were removed and stored in 10% formalin for at least 24 hours, and were
then transferred to a 30% sucrose solution for three days.  Brains were sectioned using a
cryostat and sections (50 µm) were mounted on gelatin-coated slides, stained using Cresyl
Violet, and examined under a light microscope.  Subjects whose probe and injection
cannula placements were located outside any of the targeted regions were excluded from
further analysis.
6. DATA ANALYSIS
Changes in basal ACh efflux (fmol/15 µl) across sessions and treatment groups
were analyzed using one-way repeated measures analysis of variance (ANOVAs).  Basal
efflux was then defined as the mean of the four baseline collections, and subsequent data
were expressed as percent change from that mean baseline.  Statistical analysis of drug
effects was conducted using a two-way, within-subjects ANOVA with drug GROUP and
TIME as within-subjects measures.  Significance was defined as P < 0.05, and the Huynh-
Feldt correction was utilized to reduce Type I errors associated with repeated measures
ANOVAs (Vasey and Thayer, 1987).  All statistical tests were preformed using SPSS for
windows (version 14.0).
7. ATTENTIONAL SET-SHIFTING
APPARATUS
The set-shifting maze (Figure 3) is constructed out of pressed wood (0.7 cm thick)
and is sealed with a polyurethane primer.  The maze is composed of a central platform (14
cm each side) and four arms (40 cm each) radiating from the central platform.  The arms
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are 14 cm wide with walls 20 cm in height.  A hexagonal plastic food dish was placed at the
end of each arm and was sufficiently deep where a food reward could not be seen when
entering the arm.  Maze arms varied along
two stimulus dimensions: brightness and
texture.  Two arms were covered with a
faux leather material in black and the other
two were covered in the same material in
white.  The smooth texture (on the floor)
consisted of the faux leather material
covering the walls, and the rough texture consisted of rough grade sandpaper spray painted
either black or white to correspond with the appropriate colored arms.  Arm combinations
were: white/smooth, white/rough, black/smooth and black/rough.  The maze was attached
to a rotary platform.  The holding cage used for inter-trial intervals was a standard rat
housing cage lined with corn-cob bedding.
SET-SHIFTING TRAINING
All training and testing paradigms were modeled after procedures used by Stefani
and Moghaddam (2005a).  Animals were first food restricted (given 15-20 g/day) and
maintained at a minimum of 85% of their free-fed weight.  During the pre-acclimation phase,
animals were given a food reward consisting of a sugary cereal (Froot Loops) in their home
cages to familiarize them with the taste and odor of the reward, and to reduce possible
neophobic effects of reward introduction in the maze.  Following a week of handling and
food restriction, animals began one of two phases of maze acclimation.  During the first day
of acclimation, multiple animals were placed in the maze and were allowed 10 minutes to
explore and consume any food rewards there.  Following this first day, animals were
individually placed in the maze in which all four food wells were baited with pieces (1/3 of
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an individual cereal piece) of Froot Loops.  Rats were given 10 minutes to roam freely and
explore the apparatus, to condition the rats to receiving food rewards while in the maze.  On
subsequent days of acclimation, each food well was baited with one piece of Froot Loop per
well, and rats were allowed to explore until all food had been consumed, up to 10 minutes.
Upon removal from the maze, rats were briefly placed in a holding cage before returning to
their home cages.  Surgical implantation (see above) of injection and microdialysis guide
cannulae were done following this first phase of acclimation.
During the second phase of acclimation, the maze was set up in a T configuration
(with a divider placed to block one arm).  Animals received 8 trials per day, consisting of
two starts from each arm.  Animals were placed in the central arm, allowed to turn left or
right (choosing one arm) and consume any food reward there.  Arms were reinforced
randomly.  Between trials, rats were removed from the maze and placed in a holding cage
(inter-trial interval approx. 15 s).
SET-SHIFTING TESTING
The attentional set-shifting task consists of two sessions on consecutive days, with
the maze in a T configuration as it was during the second phase of acclimation.  On day 1
(Set 1) animals were trained to discriminate between brightness (black verses white arms)
or texture (smooth verses rough arms) dimensions, and were trained to reach a criterion
performance level consisting of 8 consecutive correct trials.  Animals were allowed 2
minutes to make a ‘choice’ by which an animal had to leave the start arm and enter one
choice arm far enough so all four feet passed into the choice arm.  Animals were allowed
up to 120 trials to reach criterion, and animals who failed to learn the initial discrimination
following 120 trials were removed from study.  On day 2 (Set 2), animals were trained on
the alternative (extra-dimensional) discrimination strategy for 80 trials, regardless of
performance level (Stefani and Moghaddam, 2005a).
Page 20
20
SET-SHIFTING DATA ANALYSIS
All statistical analyses were conducted according to tests described in Stefani and
Moghaddam (2005a).  Dependent measures including trials and time to criterion (Set 1) and
time to criterion (Set 2) were analyzed using one-way analysis of variance (ANOVA).
Because the trials to criterion for Set 2 were restricted under a cap of 80 trials (Stefani and
Moghaddam, 2005a), these data were analyzed using the non-parametric Kruskal-Wallis
test with Mann-Whitney post hoc testing.  The percentage of correct scores was analyzed
for each 8-trial block (over 10 consecutive blocks) to examine performance across blocks of
trials for Set 2.  Performance across trial blocks was analyzed using mixed-design 2-way,
repeated measures ANOVAs, with drug treatment as the between subjects variable and
trial block as the within subjects measure (Stefani and Moghaddam, 2005a).  Analysis of
perseverative responding during Set 2 was conducted by comparing the percent correct
scores from each of two start-arm designations (perseveration and reinforcement arms)
within each block of trials.  Perseveration arms consisted of the start arms that yielded an
incorrect response during Set 2, but were previously reinforced during Set 1.
Reinforcement arms were designated as those yielding a correct response during Set 2
when responding according to the strategy that was successful during Set 1.  Perseverative
arm and reinforcement arm performance was analyzed by comparing percent correct
scores using mixed design 2-way, repeated measures ANOVAs with treatment group as the
between-subjects and trial block as the within-subjects variables.  Using this paradigm,
animals can make three kinds of errors in learning the new strategy for Set 2.  These
include perseverative errors where animals choose the previously reinforced dimension.
For example, animals that learned to choose the black arm during Set 1 but need to learn
the smooth arm for Set 2 would be making perseverative errors if they repeatedly chose the
black/rough (incorrect) arm over the white/smooth (correct) arm.  Animals may also make
errors in which they fail to learn the new strategy; these errors include entry into never-
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reinforced arms which includes the white/rough arm in this example.  Animals may also
make regressive errors in which animals begin to adopt the new (smooth) strategy, but then
revert back to the original rule from Set 1 (Floresco et al., 2006).
RESULTS
Guide cannulae placements
All placements were located in the mPFC. Figure 1 shows a representative
placement of this area. Any animals whose probe placements fell outside of the mPFC
were excluded from further analysis.
Manipulation of the KYN pathway to decrease endogenous levels of KYNA
This manipulation validated the ability of a KAT II inhibitor, UPF-874, to
subsequently decrease KYNA in the mPFC. Figure 2 illustrates the effects of 5 mM UPF-
874 on KYNA efflux (n = 5). Administration of UPF-874 significantly decreased KYNA levels
across collections (TIME, F11,44 = 8.643, P < 0.001). Data from this experiment was
gathered from our collaborators at the University of Maryland (unpublished observations,
Wu, H.Q. and Schwarcz, R.).
Ability of KYNA to regulate basal cortical ACh transmission
This experiment examined the contribution of physiologically-relevant
concentrations of KYNA to the basal regulation of cortical ACh release.  Figure 3 illustrates
the effects of aCSF-vehicle, 100 nM KYNA, 5 mM UPF-874, and 100 nM KYNA + 5 mM
UPF-874 on cortical ACh efflux (n = 7).  Basal levels of ACh efflux remained stable over the
four dialysis sessions (SESSION, F3,18 = 0.808, P = 0.474), and across all drug treatments
(DRUG, F3,18 = 3.181, P = 0.077), as revealed by one-way ANOVAs.  Basal levels of ACh
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(mean ± S.E.M., fmol/15 µl) were 3.1 ± 0.8, 5.2 ± 0.7, 2.7 ± 0.3, and 5.4 ± 1.1 for aCSF, 100
nM KYNA, 5 mM UPF-874, and 100 nM KYNA + 5 mM UPF-874 sessions, respectively.
Given that basal levels of ACh efflux did not differ over session or group, all subsequent
values were expressed and analyzed as a percent change from session baseline.  Intra-
cortical perfusion of drugs led to differential effects on cortical ACh efflux (DRUG, F3,18 =
29.080, P < 0.001).  These effects were found to vary across collection interval (TIME F10.60
= 3.638, P = 0.001; DRUG x TIME, F30,180 = 2.787, P = 0.002).  Considering the overall
main effects comparing all four treatment groups, a series of smaller 2-way ANOVAs were
conducted to look for differences between treatment groups.
Administration of 5 mM UPF-874 significantly increased ACh levels above the
vehicle aCSF session (DRUG, F1,6 = 44.826, P < 0.001; TIME, F10,60 = 4.899, P < 0.001;
DRUG X TIME, F10,60 = 2.930, P = 0.032). UPF-874 was significantly higher than aCSF
within the first 15 minutes of perfusion (collection 5, t5 = -3.773, P =0.009). In addition,
administration of UPF-874 significantly increased ACh levels above KYNA (DRUG, F1,6 =
50.520, P < 0.001; TIME, F10,60 = 3.186, P = 0.004; DRUG X TIME, F10,60 = 5.358, P <
0.001). UPF-874 was significantly higher than KYNA within the first 15 minutes of perfusion
(collection 5, t5 = -3.887, P =0.008). Furthermore, co-perfusion of UPF-874 and exogenous
KYNA was able to attenuate the UPF-874–mediated increases in ACh as levels between
UPF-874 and the combination treatment were significantly different (DRUG, F1,6 = 67.171, P
< 0.001; TIME, F10,60 = 4.595, P < 0.001; DRUG X TIME, F10,60 = 1.020, P = 0.003). UPF-
874 was significantly higher than co-perfusion of both drugs within the first 15 minutes of
perfusion (collection 5, t5 = 5.093, P =0.002). Interestingly, this highlights the role of
astrocytic activity in the modulation of ACh transmission.
There was a significant effect of DRUG between the administration of 100 nM KYNA
and the combination treatment of KYNA and UPF-874 (F1,6 = 6.369, P = 0.045), but there
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was no effect  for TIME (F10,60 = 0.925, P = 0.517) or DRUG X TIME (F10,60 = 1.020, P =
0.436).
Overall, these results suggests that KYNA, and hence astrocytic activity, negatively
modulates PFC ACh release.  KYNA also tonically inhibits basal ACh release as the KAT II
mediated reduction in KYNA synthesis markedly increases cortical ACh.
Manipulation of the KYN pathway to increase endogenous levels of KYNA
This manipulation validated the ability of increased precursor levels, L-KYN, to
subsequently increase KYNA levels in the mPFC. Figure 4 illustrates the effects of a
systemic injection of L-KYN (50mg/kg) on KYNA efflux (n = 5). Administration of L-KYN
significantly increased KYNA levels across collections (TIME, F15,45 = 124.825, P < 0.001).
Data from this experiment was gathered from our collaborators at the University of
Maryland (unpublished observations, Wu, H.Q. and Schwarcz, R.).
Effect of increased endogenous levels of KYNA on rule acquisition
This experiment examined whether increased KYNA levels results in a general
cognitive impairment by impairing initial rule acquisition. Figure 5 represents performance of
saline treated animals (n = 6) and kynurenine (50 mg/kg) treated animals (n = 6) on Day 1
of the set-shifting task. On average (mean ± SEM), saline treated animals required 36.5 ±
9.2 trials and kynurenine treated animals required 43.2 ± 9.7 trials to reach criterion.
Therefore, this indicates that elevations in KYNA pre-Set 1 did not have a significant effect
on the number of trials to reach criterion (F1,11 = 1.491, P = 0.250). Furthermore, while the
% correct varied over BLOCK (F9,90 = 8.466, P < 0.001), they did not vary by BLOCK X
GROUP (F9,90 = 0.464, P =0.831) or GROUP (F1,10 = 0.514, P = 0.490). Therefore, both the
saline and kynurenine treated animals learned at a similar rate. Trials to criterion on Day 2
of testing for pre-Set 1 treated animals were analyzed using the Kruskal-Wallis test for
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nonparametric data because of the imposed 80-trial cap in this test. On average (mean ±
SEM), saline treated animals required 57.4 ± 7.7 trials and kynurenine treated animals
required 47.4 ± 9.2 trials to reach criterion. Therefore, elevations in endogenous KYNA
levels pre-Set 1 did not have a significant effect on the number of trials to required to reach
criterion on Day 2 of testing (X2 = 0.521, P = 0.470). Therefore, increased KYNA levels
does not impair rule acquisition as no significant difference in the number of trials required
to reach criterion on either Day 1 or Day 2 testing were found. Additionally, there was no
difference in % correct starts from perseverative arms (F1,11 = 0.144, P = 0.712) or
reinforcement arms (F1,11 = 0.403, P = 0.540) for kynurenine and saline treated animals.
Effect of increased endogenous levels of KYNA on performance in a cognitive
flexibility task
This experiment examined whether increased KYNA levels results in impaired
flexible responding. Figure 6 represents performance of saline treated animals (n = 7),
kynurenine (50 mg/kg) treated animals (n = 7) that reached criterion (n = 2), and kynurenine
treated animals that did not reach criterion (n = 5) on Day 2 of the set-shifting task. On
average (mean ± SEM) for Day 1 of testing, saline treated animals required 39.4 ± 18.4
trials and kynurenine treated animals required 38.3 ± 10.6 trials to reach criterion.
Therefore, this indicates that elevations in KYNA pre-Set 1 did not have a significant effect
on the number of trials to reach criterion (F1,13 = 0.020, P = 0.889). Trials to criterion in Set
2 were analyzed using the Kruskal-Wallis test for nonparametric data because of the
imposed 80-trial cap in this test. On average (mean ± SEM) for Day 2 of testing, saline
treated animals required 50.4 ± 5.0 trials and kynurenine treated animals required 56.3 ±
7.2 trials to reach criterion. While the % correct choices of Set 2 varied over BLOCK (F9,108
= 5.508, P < 0.001), they did not differ based on drug treatments (BLOCK X GROUP; F9,108
= 1.385, P = 0.227) nor did the two treatment groups vary from one another over the
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duration of the task (GROUP; F1,12 = 2.758, P = 0.123). Interestingly, elevations in
endogenous KYNA levels pre-Set 2 did have a significant effect on the number of trials
required to reach criterion on Day 2 of testing (X2 = 4.545, P = 0.033) which reflects
impairment on the EDS of the task. Additionally, there was no difference in percent correct
starts from perseverative arms (F1,13= 2.315, P = 0.154) or reinforcement arms (F1,13 =
0.072, P = 0.793) for kynurenine and saline treated animals. Therefore, impairments were
not due to an inability to abandon the previously reinforced stimuli.
DISCUSSION
The results of these experiments contributed further knowledge regarding the ability
of KYNA to regulate chemotransmission and behavior. This study revealed two major
findings. The first experiment demonstrated that (1) KYNA, and hence astrocytic activity,
negatively modulates basal cortical ACh transmission (Figure 3). More importantly, the
second experiment determined a functionally significant role for KYNA in cognitive
processing as (2) elevated KYNA levels specifically impaired the ability of animals to
perform an EDS that was not due to a general cognitive impairment as increasing levels of
this metabolite did not impair rule acquisition (Figures 5,6). A discussion of the issues
raised by each finding is included below.
KYNA to regulate basal cortical ACh transmission
This study demonstrates the ability of an astrocyte-derived metabolite, KYNA, to
negatively modulate basal cortical cholinergic transmission. While this is the first study to
reveal that astrocytic activity modulates cortical cholinergic transmission, it does not
elucidate the precise molecular and cellular events that mediate its regulatory capacity.
Additionally, it is extremely unlikely that this is a direct effect as there is no evidence for the
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presence of _7nAChR autoreceptors on cholinergic terminals or interneurons in the PFC
(Von Engelhardt et al., 2007). Therefore, the role of KYNA in the regulation of ACh
transmission is most likely mediated through mechanisms that indirectly influence
extracellular ACh release. Interestingly, the localization of _7nAChR is well documented on
glutamatergic nerve terminals (Rassoulpour et al., 2005). Furthermore, _7nAChR activation
is normally associated with direct facilitation of glutamatergic transmission in the brain
(Gray et al., 1996; Fu et al., 2000). As such, the ability of KYNA to attenuate glutamatergic
function in vivo (Pellicciaro et al., 1994; Harris et al., 1998; Cozzi et al., 1999; Schwarcz et
al., 1999) can be attributed to its inhibitory action on _7nAChRs on glutamatergic terminals.
Therefore, KYNA may bi-directionally regulate Glu release through its inhibitory actions on
_7nAChRs located on glutamatergic terminals.
However, as previously mentioned, there is also a role for KYNA in the regulation of
DA chemotransmission (Rassoulpour et al., 2005; Wu et al., 2007).  As such, any proposed
mechanism for regulatory roles of KYNA must explain how both neurotransmitter systems
are simultaneously affected. In fact, it has been proposed that the _7nAChRs regulate
glutamate release (Kaiser & Wonnacott, 2000), which in turn controls extracellular DA via a
glutamate receptor subtype, α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA),
situated on dopaminergic nerve terminals (Cheramy et al., 1986; Imperato et al., 1990;
Leviel et al., 1990; Moghaddam & Bolinao, 1994; Borland & Micheal, 2004).
This sequential activity is consistent with demonstration that galantamine, which at
low concentrations potentiates _7nAChRs allosterically (Santos et al., 2002; Sanochocki et
al., 2003), prevents the KYNA-induced reduction of extracellular dopamine. Additionally, the
ability of KYNA to influence extracellular DA levels likely involves its inhibitory action on
_7nAChR rather than NMDA receptors. Evidence for this is derived from studies where the
effect of KYNA on DA was not influenced by co-perfusion with D-serine, also an agonist of
the glycineB receptor (Schell, 2004). Additionally, the KYNA-derivative, 7-Cl-KYNA, which is
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a selective glycineB receptor antagonist, is incapable of influencing extracellular DA levels
(Rassoulpour et al., 2005). Also, AMPA receptors are located on cholinergic neurons in
several brain regions (Bernard et al., 1997; Bloomfield et al., 2007).  Therefore, this would
facilitate the ability of KYNA to indirectly influence ACh transmission.
Elevated KYNA levels impaired extra-dimensional shifting without impairing rule
acquisition
We proposed that since schizophrenics present with elevated KYNA levels and
impaired cognitive flexibility, increases in this metabolite may mediate this behavioral
impairment. Interestingly, this was not due to a general cognitive impairment as increasing
KYNA levels does not impair rule acquisition. These data present an interesting parallel to
the human literature that indicates schizophrenics are impaired on ED shifting in the WCST
(Robbins, 2007; Pantelis et al., 1999). Importantly, this maze-based set-shifting task was
developed to reveal many of the same cognitive operations highlighted by the WCST
(Birrell & Brown, 2000). Interestingly, neuroleptic treatment reduces KYNA levels
suggesting a potential mechanism by which chronic antipsychotic treatment may alleviate
some aspects of cognitive dysfunctions in patients (Ceresoli-Borrini et al., 2006).
Moreover, previous studies suggest additional roles for KYNA in other symptoms of
schizophrenia. For instance, schizophrenics exhibit pronounced deficits in
psychophysiological measures of sensory gating (Patterson et al., 2000). Moreover, both
glutamatergic and cholinergic mechanisms are implicated in the neurobiological basis of
auditory gating as administration of a noncompetitive NMDA receptor antagonist (MK-801;
Miller et el., 1992) and _7nAChR antagonists (Freedman et al., 1997) disrupts auditory
gating. Shepard et al. demonstrated that the association of elevated brain levels of KYNA in
rats with auditory gating impairments was not attributable to the glutamate receptor
antagonist properties of the metabolite (2003). In addition, prepulse inhibition (PPI) of the
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acoustic startle reflex is an operational measure of sensorimotor gating that is reduced in
schizophrenia (Braff et al., 1978). Erhardt et al. (2004) discovered that brain KYNA serves
as an endogenous modulator of PPI, which is consistent with a hypothesis that aberrations
in KYNA synthesis may contribute to various pathophysiologies of schizophrenia (2004).
While these studies suggest a role for KYNA mediated psychopathologies, a recent
study has also demonstrated the ability for KYNA to impair cognitive functions like spatial
working memory (Chess et al., 2007) that was not attributed to altered locomotor activity or
motivation to consume food. Given this evidence, we proposed KYNA may also impair
behavioral flexibility, an executive function disrupted in schizophrenia.
Although we discovered a role for KYNA in the regulation of cognitive flexibility, this
may not be strictly mediated through a cholinergic mechanism as literature is mixed on the
role of ACh in an attentional set-shifting task. One study that maintains ACh transmission is
necessary to shift attention examined the effects of a muscarinic antagonist, scopolamine.
Interestingly, systemic administration of scopolamine impairs EDS in the task (Chen et al.,
2004). However, the central location of this cholinergic mechanism has yet to be specified.
On the other hand, a few recent studies suggest the role of cholinergic mechanisms
in set shifting is not paramount to the EDS in this task. For instance, selective lesions of
basal forebrain cholinergic neurons with 192-IgG-saporin did not result in impairments on
shifting of an attentional set (Tait & Brown, 2008). Therefore, perhaps performance in this
task is dependent upon a complex interaction amongst multiple neurotransmitter systems
like DA, Glu, and ACh (Block et al., 2007). For example, systemic administration of the MK-
801 impaired the EDS required of the task (Stefani & Moghaddam, 2005). Interestingly, this
impairment is caused by an increased number of perseverative errors, in contrast to our
findings. Additionally, Stefani & Moghaddam also examined the ability of MK-801
administration during a critical period of brain development to impair flexible responding
(2005b). This period in rats is equivalent to the prenatal second trimester of primate
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development and most neurodevelopmental models of schizophrenia focus on this
postnatal period (Lipska et al., 2002). They discovered that a transient disruption of NMDA
receptor function using MK-801 during this critical period impaired cognitive flexibility due to
increased perseverative behavior. Furthermore, acute injections of phencyclidine (PCP)
induced EDS deficits in an attentional set-shifting task, and moreover, atypical
antipsychotics significantly improved the PCP-induced cognitive deficit (McLean et al.,
2008). Also, in addition to NMDA receptor mediated impairments in flexible responding,
AMPA receptor antagonists also impaired EDS. However, this effect can be distinguished
from MK-801 induced deficits in the EDS of the task because it produces a more general
cognitive deficit (Stefani et al., 2003). Therefore, these studies support a KYNA based
targeting of the Glu system in impairments seen in the present study.
 In addition, dopaminergic neurotransmission in the cortex also plays a role in set-
shifting behavior as shown in laboratory animals (Floresco et al., 2006; Stefani &
Moghaddam, 2006) and human volunteers (Mehta et al., 2004). Moreover, cortical
(Laplante et al., 2004; Del Arco et al., 2007) and NAC (Zmarowski et al., 2005; Brooks et
al., 2007) dopamine receptor activity can also regulate cortical ACh levels.
Collectively, this literature provides a framework in which to view and understand
our observations that KYNA impaired performance in a set-shifting task. Unfortunately, the
literature conflicts regarding the relative contribution of cholinergic mechanisms mediating
cognitive flexibility; however, their likely contribution cannot be completely dismissed as
ACh transmission may be faciliatory for DA and Glu-mediated functioning that appears
integral for this task. Additionally, the critical neural structures for cholinergic involvement in
set-shifting may comprise distributed systems and not be restricted to those within the
neocortex (Chen et al., 2004).
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FUTURE DIRECTIVES
Currently, studies are underway to determine if bilateral, intra-cortical perfusions of
L-KYN or KYNA will also impair flexible responding in a perceptual set-shifting task. We
predict that both of these manipulations will do so as a systemic injection of L-KYN also
impaired the ability to perform extra-dimensional shifts in the task. However, local
manipulations will provide greater validity and reinforce the conclusions generated from the
present experiments. In addition, it would be interesting to examine whether set-shifting
deficits were attenuated by co-administration of typical or atypical neuroleptics as chronic
treatment with these are known to reduce levels of KYNA. Moreover, attempts should be
made to dissociate the contribution of cholinergic versus glutamatergic transmission in an
attentional set-shifting task.
CONCLUSIONS
The present study is both innovative and significant because this is the first study to
reveal that astrocytic activity modulates cortical cholinergic transmission. This research also
demonstrated a role for KYNA in the regulation of prefrontally-mediated cognitive flexibility.
Collectively, these studies may help uncover a role for KYNA-ACh dysfunction in
schizophrenia, which could facilitate the development of more efficacious pharmaceuticals
utilized for the treatment of cognitive deficits seen in neuropsychiatric disorders.
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FIGURES AND FIGURE LEGENDS
Figure 1.  Representative histology for mPFC probe placements. (A) A schematic depiction
of an mPFC placement. Guides were implanted so that when probes were inserted, the
membrane tip (3.0 mm) was located at AP +4.2, LM +0.6, DV -0.6 from dura pointing 20°
rostral. (B) A representative photomicrograph from a subject with the mPFC placement that
is illustrated in (A). Due to the angle at which the guide cannula and probe were positioned,
the arrow points to the site of termination of the dialysis probe. All coordinates were based
upon Paxinos and Watson (1998).
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Figure 2. Mean (± SEM) kynurenic acid (KYNA) efflux in the mPFC of animals (n = 5)
receiving vehicle (artificial cerebral spinal fluid, aCSF) or a moderate concentration of a
kynurenine aminotransferase II inhibitor UPF-874 alone (5 mM) into the mPFC over the
course of one microdialysis session. Following a 3-h washout period, four baseline samples
were collected (collections 1-4). This was followed by the administration of aCSF + drug
(vehicle, UPF-874). After the 60 min perfusion of aCSF + drug (collections 5-8), aCSF
alone was perfused for 60 min (collections 9-12) until the end of the microdialysis period.
UPF-874 alone significantly decreased KYNA efflux below vehicle. Data from this
experiment was gathered from our collaborators at the University of Maryland (unpublished
observations, Wu, H.Q. and Schwarcz, R.).
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Figure 3. Mean (± SEM) acetylcholine (ACh) efflux in the mPFC of animals (n = 8)
receiving, in counterbalanced order, vehicle (artificial cerebrospinal fluid, aCSF), a
kynurenine aminotransferase II inhibitor UPF 874 alone (5 mM), a physiologically relevant
concentration of kynurenic acid (KYNA) alone (100 nM), and co-administration of UPF 874
+ KYNA into the mPFC during four separate microdialysis sessions. Following a 3-h
washout period, four baseline samples were collected (collections 1-4). This was followed
by the administration of aCSF + drug (vehicle, KYNA, UPF 874, or KYNA + UPF 874) for 60
min (collections 5-8). After the 60 min perfusion of aCSF + drug, aCSF alone was perfused
for 45 min until the end of the microdialysis period (collections 9-11). KYNA alone reduced
ACh efflux below vehicle. UPF 874 alone significantly increased ACh efflux above vehicle.
Co-administration of KNYA and UPF 874 resulted in an ACh efflux similar to that produced
by vehicle alone. Therefore, the increase in ACh efflux produced by UPF 874 was blocked
by concurrent perfusion of KYNA.
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Figure 4. Mean (± SEM) kynurenic acid (KYNA) efflux in the mPFC of animals (n = 5)
receiving a systemic injection of kynurenine (50 mg/kg). Vehicle (artificial cerebral spinal
fluid, aCSF) was constantly perfused through the microdialysis probe in the mPFC.
Following a 3-h washout period, four baseline samples were collected (collections 1-4). This
was followed by a systemic injection of kynurenine after which multiple collections (5-16)
were taken to allow KYNA levels to return to baseline. Following the injection, a max
increase in KYNA was observed approximately 45 min later. Data from this experiment was
gathered from our collaborators at the University of Maryland (unpublished observations,
Wu, H.Q. and Schwarcz, R.).
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Figure 5. Mean (± SEM) % correct responses by Block for the acquisition of the Set 1
testing process as represented by Blocks. Each Block represents 8 trials (80 total trials).
Therefore, early-task performance is represented by % correct responses during Blocks 1-
3, mid-task performance is reflected by % correct responses during Blocks 4-7, and end-
task performance is indicated by % correct responses during Blocks 8-10. Both the saline
treated rats (control; n = 6) and the kynurenine (50 mg/kg) treated rats (n = 6) learn the new
rule as indicated by the acquisition curve or gradual improvement in responding over time.
Both groups learned the new rule, at a similar rate, and by Block 7 successfully reached
criterion, 8 consecutive correct trials.
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Figure 6. Mean (± SEM) % correct responses by Block for the acquisition of the Set 2
testing process as represented by Blocks. Each Block represents 8 trials (80 total trials).
Therefore, early-task performance is represented by % correct responses during Blocks 1-
3, mid-task performance is reflected by % correct responses during Blocks 4-7, and end-
task performance is indicated by % correct responses during Blocks 8-10. The kynurenine
(50 mg/kg) treated animals (n = 7) were subdivided into those that reached criterion (n = 2)
and those that did not reach criterion (n = 5). All groups began the Set 2 testing process
achieving a correct response to the new stimulus of approximately 50% because of
responding to the previous rule. The kynurenine treated animals that did reach criterion
performed at a similar rate to the saline treated animals and both groups learned the new
rule as indicated by the acquisition curve. However, the kynurenine treated animals that did
not reach criterion were unsuccessful in shifting behavioral response strategies as there is
no indication of an acquisition curve over time. They consistently achieved a correct
response about %50 of the time.
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